Received Sep 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (MODERNA)) | MODERNA | UNK | — | IM |
covid-19; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (covid-19) in a 64-year-old female patient who received SPIKEVAX NOS (SPIKEVAX NOS) for COVID-19 prophylaxis. The patient's past medical history included Transplant. Concurrent medical conditions included Cancer and Immunocompromised. On an unknown date, the patient received dose of SPIKEVAX NOS (SPIKEVAX NOS) (Intramuscular use) 1 dosage form. In May 2023, the patient experienced COVID-19 (covid-19). At the time of the report, COVID-19 (covid-19) outcome was unknown. Relevant Medical History (vaccines within the past 4 weeks, medical conditions) were reported as none. No concomitant medication was reported. The patient received Moderna vaccines and boosters since 2021, initially received doses a month apart due to being immunocompromised. She underwent a transplant and was advised to get three Moderna vaccines post-transplant, which she received in Dec-2021, Jan-2022, and Feb-2022. She had consistently received boosters each fall but recently inquired about the new mRNA vaccines, mRNA-1273.815 (mNEXSPIKE) and mRNA-1273.214 (mSPIKEvax). Despite these precautions, she did contract COVID-19 once back in May 2023. Due to these reactions, she preferred a lower dosage of the vaccine and asked her healthcare provider if a lower dose would offer adequate protection. The patient seek assurance that a lower dose will protect her as effectively as a higher dose, though she did not receive a satisfactory response from her local healthcare provider. It was unknown if the patient experienced any additional symptoms or events. No treatment medication was reported. This case was linked to MOD-2025-789068 (Patient Link). Reporter did not allow further contact
Cancer; Immunocompromised
Medical History/Concurrent Conditions: Transplant